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CD4+CD25+Foxp3+ regulatory T cells (Tregs) play a key
role in the induction and maintenance of peripheral
tolerance. Rapid and transient production of IFN-c by
Tregs from mice tolerized to alloantigen in vivo has
been shown to be critical for their regulatory func-
tion. This IFN-c has the potential to affect the func-
tion of cells present in the same local microenviron-
ment as the Tregs, including the Tregs themselves.
Here we investigated the mechanism by which IFN-c
produced by Tregs triggered signaling pathways in al-
loantigen reactive Tregs themselves thereby inﬂuenc-
ing their function in vivo. We show that IFN-c produc-
tion and STAT1 activation was increased, while STAT1-
dependent PKB/AKT activation was downregulated in
alloantigen reactive Tregs. Further, the activation of
STAT1 was blocked in IFN-c receptor deﬁcient as well
as IFN-c–deﬁcient Tregs, suggesting that IFN-c pro-
duced by the alloantigen reactive Tregs might act in an
autocrine manner to induce STAT1 activation. Impor-
tantly, STAT1-deﬁcient Tregs failed to control allograft
rejection in vivo. Overall, these ﬁndings suggest that
the IFN-c–induced STAT1-PKB/AKT signaling pathway
plays a key role in upregulating the ability of alloanti-
gen reactive Tregs to control graft rejection in vivo.
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Introduction
CD4+CD25+Foxp3+ regulatory T lymphocytes (Tregs) are
specialized T cells that play a critical role in the control
of immune homeostasis, the maintenance of immunolog-
ical self-tolerance and in the regulation of antigen-induced
responses including tumor immunity and transplantation
(1). A key role for IFN-c in tolerance induction has been
demonstrated in allergy, cell and organ transplantation, and
autoimmunity including experimental autoimmune allergic
encephalomyelitis (EAE) and glomerulonephritis (2–4). It
has been reported that a signiﬁcant amount of IFN-c is pro-
duced by PMA-/ionomycin-stimulated Foxp3+ Tregs in vitro
(5), and that Tregs are unable to prevent collagen induced
arthritis in IFN-c receptor deﬁcient (IFN-cR−/−)m i c e( 6 ) .I n
addition, alloantigen reactive CD4+CD25+ Tregs from to-
lerized mice, which were induced in vivo by pretreatment
with donor alloantigen under the cover of anti-CD4 ther-
apy, upregulate IFN-c expression rapidly and transiently
with enhanced regulatory activity (7). However, it remains
unclear how IFN-c produced by Tregs themselves might
inﬂuence their suppressive function in vivo.
IFN-c has been identiﬁed as the activator of the JAK-STAT1
signal transduction pathway in various cell types through
its speciﬁc receptor, the IFN-cR (8). Binding of IFN-c to
IFN-cR induces IFN-cR oligomerization and activation of
JAK1 and JAK2 by trans-phosphorylation. The activated
JAKs phosphorylate the intracellular domain of the IFN-cR
that thenserves as a docking site for STAT1. STAT1is phos-
phorylated on tyrosine 701, undergoes dimerization and
translocates to the nucleus to promote IFN-c–regulated
gene expression (9). It has been reported that STAT1-
deﬁcient mice have reduced numbers of naturally occur-
ring CD4+CD25+ Tregs and develop EAE with increased
frequency (10). Despite these observations, whether IFN-
c triggered STAT1 activation plays an important role in reg-
ulatingthesuppressivefunctionofTregsinvivo isnotclear.
In addition, it has been reported that biological response
to IFN-c is also pleiotropic since the cytokine engages
multiple signal-transduction pathways, including STAT1 de-
pendent PI3’K-PKB/AKT, MEK-ERK or STAT1 independent
pathways (9). Previous studies have reported that mouse
CD4+CD25+ T cells reduce activation of PKB/AKT follow-
ing TCR/CD28 stimulation (11) and expression of the ac-
tive form of AKT suppresses the function of CD4+CD25+
Tregs without affecting Foxp3 expression (12). However,
this remains controversial since others showed that con-
tinued TCR signaling and constitutive PI3K/AKT/mTOR
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activity regulated Foxp3 expression in CD4+Foxp3+ cells
(13). In addition, IL-2 plays an essential role in the devel-
opment of CD4+CD25+ T cells during the neonatal pe-
riod as well as in the maintenance of the Treg popula-
tion in vivo (14). It has been suggested that IL-2 regu-
lates Foxp3 expression in CD4+CD25+ T cells through a
STAT5-dependent mechanism (15). Therefore, we were in-
terested in whether AKT, ERK or STAT5 activity is linked to
the IFN-c–STAT1 pathway and enhances the suppressive
function of alloantigen reactive Tregs.
In this study, we show that the phosphorylation level of
STAT1, but not of STAT5 or ERK1/2, was speciﬁcally in-
creased in Tregs from mice tolerized to alloantigen that
also upregulated production of IFN-c. By contrast, STAT1-
dependent PKB/AKT activity was downregulated. Notably,
STAT1-deﬁcient Tregs from tolerized mice failed to pro-
tect allografts from rejection in vivo. Moreover, STAT1 ac-
tivation was impaired in alloantigen reactive Tregs isolated
from tolerized IFN-cR–deﬁcient as well as IFN-c–deﬁcient
mice. These data suggest that IFN-c produced by alloanti-
gen reactive Tregs might act on Tregs themselves through
an autocrine pathway. Our results propose a previous un-
characterized role of IFN-c that triggers the STAT1-AKT





129S6/SvEv (129,H2b), C57BL/6(BL6,H2b),BALB/c(H2d), and129S6/SvEv
Rag2−/− (H2b), C57BL/6 Rag1−/− (H2b), IFN-c −/−C57BL/6 (H2b), IFN-c Re-
ceptor−/− C57BL/6 (H2b) mice were bred in the SPF facility, Biomedical Ser-
vices, John Radcliffe Hospital. STAT1−/−129S6/SvEv mice were purchased
from Taconic.
Induction of tolerance, adoptive transfer and skin transplantation
To induce tolerance, adult na¨ ıve mice were pretreated with anti-CD4 an-
tibody YTS177 (200 lg i.v days −28 and −27; timing denoted relative to
day 0 the time of adoptive transfer) in combination with an infusion of al-
loantigen (BALB/c (H2d) (typically 250 lL whole allogeneic blood i.v. on day
−27 and day −1). These were designated tolerized mice. In some experi-
ments, as controls adult mice were treated with an infusion of alloantigen
only as above, 1 day before isolation of CD4+CD25+ T cells. There were
designated alloantigen-primed mice. In the adoptive transfer protocol, T-
cell–deﬁcient 129S6/SvEv Rag2−/− (H2b) or C57BL/6 Rag1−/− (H2b) mice
were reconstituted i.v. with syngeneic fractionated T cells isolated from
tolerized, alloantigen-primed or unmanipulated mice on day 0. The day after
reconstitution (day 1), all mice received a BALB/c skin graft as described
previously (7). Graft rejection was deﬁned as complete destruction of the
skin graft.
Antibodies and reagents
Fludarabine and PD98059 were purchased from Sigma. Hybridomas YTS
177.9 (anti-CD4) was kindly provided by Professor Herman Waldmann.
Mouse CD4+ T-cellisolation kits,GolgiStopreagent,Fix/Perm solution,anti-
p-STAT1 (pTyr701), anti-p-PKB/AKT (pSer472/Ser473), anti-PKB/AKT, anti-p-
ERK1/2 (pThr202/pTyr204), APC or FITC-labelled anti-CD4 mAb, PE-anti-p-
STAT1 (pTyr701), PE-anti-CD25 mAb, PE-Cy7-anti-CD25, anti-CD16/CD32
mAb, FITC-labeled anti-IFN-c, biotin-anti-IFN-cRa, biotin-anti-IFN-cRb,P E
streptavidin were purchased from BD Biosciences (Oxford, UK). Anti-
phospho-STAT5a/b (pTyr694/699) was from Millipore (Upstate) and ECD-
anti-CD4 was from Beckman Coulter. Anti-Foxp3 (FJK-16s) and Foxp3 intra-
cellular staining kits were purchased from eBioscience.
Cell preparation
Single-cell suspensions from mouse spleen were isolated as previously
described (16). CD4+CD25+ and CD4+CD25− T cells were puriﬁed by ﬂow
cytometry using a FACSAria (Becton Dickinson) for in vivo experiments.
FACS sorted populations were >99% pure.
Flow cytometric analysis
Standard surface and intracellular cytokine staining were preformed as de-
scribed earlier (5). Data were acquired using a FACSAria and analyzed using
the Diva software package (BD Biosciences).
Immunoblotting and densitometry
Cell lysates were prepared for SDS-PAGE followed by immunoblotting as
previously described earlier (28). ECL ﬁlms were scanned and the levels of
protein phosphorylation or expression were quantiﬁed using ImageJ densit-
ometry software. Data are expressed as relative ratios (R) when compared
to na¨ ıve samples as follows: R = (Dphos/Dtotal):(Dn-phos/Dn-total). Dphos
is the density of the phosphorylated protein, Dtotal is the density of the
total protein or actin, Dn-phos is the density of the phosphorylated protein
from the na¨ ıve sample and Dn-total is the density of the total protein or
actin from the na¨ ıve sample.
Statistical analysis
Data are presented as mean ± SD. The Student’s t-test was used to com-
pare two independent groups where the data were normally distributed.
Graft survival data analyzed by using the Kaplan–Meier log-rank test were
presented as median survival time (MST). Differences were considered to
be signiﬁcant when p < 0.05.
Results
The activation of STAT1, but not STAT5 or ERK1/2, is
speciﬁcally enhanced in alloantigen reactive
CD4+CD25+Foxp3+ T cells from alloantigen-tolerized
mice
Operational tolerance to alloantigen in vivo can be induced
in adult mice by pretreatment with donor alloantigen under
the cover of anti-CD4 antibody followed by alloantigen spe-
ciﬁc reactivation 24 h before transplantation (16). We used
the same protocol to pre-treat mice and these mice are re-
ferred to throughout the paper as ‘tolerized mice’ for clarity
(see Materials and Methods). It has been demonstrated
that alloantigen reactive CD4+CD25+ T cells are present
in these tolerized mice and that such mice accept donor-
type cardiac allografts indeﬁnitely without the need for ad-
ditional immunosuppression. Therefore, these alloantigen
reactive CD4+CD25+ T cells from tolerized mice are also
referred to “tolerized CD4+CD25+ T cells” throughout for
clarity (17,18).
We initially found that 4 × 105 tolerized CD4+CD25+ T
cells puriﬁed from the spleens of 129S6/SvEv (H2b)m i c e
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Figure 1: STAT1 phosphorylation is speciﬁcally upregulated in CD4+CD25+Foxp3+ T cells from tolerized mice that show an
enhanced ability to prevent skin graft rejection. (A) Regulation of skin graft rejection by tolerized CD4+CD25+ T cells. 129S6/SvEv
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Figure 1: (Continued) Rag2−/− mice reconstituted with 2 × 105 CD4+CD25− T cells (Teff) from 129S6/SvEv mice acutely reject BALB/c
skin grafts (n = 6, mean survival time [MST] = 19 days). Cotransfer of 4 × 105 tolerized CD4+CD25+ T cells (tolerized Tregs) with 2 × 105
syngeneic na¨ ıve Teff prevented rejection of BALB/c skin grafts (n = 8, MST > 80 days). In contrast, cotransfer of 4 × 105 alloantigen-primed
CD4+CD25+ cells together with 2 × 105 syngeneic na¨ ıve Teff resulted in rejection of BALB/c skin grafts (n = 6, MST = 26 days). BALB/c
skin transplants were performed on day 1. Data shown represent three independent experiments. p = 0.0071, tolerized Tregs versus
alloantigen primed; p < 0.0001, tolerized Tregs versus Teff only; p = 0.0005, alloantigen-primed CD4+CD25+ T cells versus Teff only. (B)
CD4+CD25+ T cells puriﬁed from tolerized, alloantigen-primed or unmanipulated na¨ ıve mice were prepared for SDS-PAGE electrophoresis
followed by immunoblotting with anti-phospho-STAT1a/b (Tyr701) (upper panel), anti-phospho-ERK1/2 (pT202/pY204) (middle panel) or
anti-actin Ab (lower panel). (C) CD4+CD25+ T cells from tolerized, alloantigen-primed or unmanipulated na¨ ıve mice or CD4+CD25− T cells
activated with allogeneicirradiated splenocytes together with IL -2 for 48 h in vitro were prepared for immunoblotting with anti-p-STAT5a/b
mAb (upper panel). Data are expressed as the relative ratios in the right histograms as described in Materials and Methods. The data
shown are representative of three independent experiments (∗p < 0.05). (D) Splenocytes were isolated from tolerized or unmanipulated
C57BL/6 mice and stained with anti-CD4 followed by intracellular anti-Foxp3 and anti-p-STAT1 staining. Events were gated in CD4+Foxp3+
or CD4+Foxp3− populations to assess the levels of p-STAT1 by FACS analysis. FACS proﬁles are representative of three independent
experiments.
tolerized to BALB/c (H2d) alloantigen 24 h after antigen-
speciﬁc reactivation in vivo can prevent the rejection of
BALB/c skin grafts initiated by 2 × 105 CD4+CD25− T
cells from their na¨ ıve counterparts (MST >80 days; six
of the eight recipients accepted BALB/c skin allografts for
>100 days; Figure 1A). However, 4 × 105 recently acti-
vated CD4+CD25+ T cells isolated 24 h after alloantigen
infusion into na¨ ıve mice (designated ‘alloantigen primed
CD4+CD25+ T cells’) were unable to prevent rejection (i.e.
MST = 26 days, ﬁve of the six recipients rejected BALB/c
skin allografts; Figure 1A). Similar data were obtained in
C57BL/6 (H2b) mice (data not shown).
To investigate the molecular mechanisms triggered in
these tolerized Tregs, STAT1 activation in CD4+CD25+ T
cells puriﬁed from tolerized mice was determined by im-
munoblottingusinganti-phospho-STAT1antibody.Thelevel
of phospho-STAT1 was compared to that from alloantigen-
primed or na¨ ıve CD4+CD25+ T cells. The active forms of
both STAT1a (91KD) and STAT1b (84KD) could be detected
by anti-phospho-STAT1 (Tyr701) in CD4+CD25+ T cells,
with STAT1a present at a higher concentration compared
with STAT1b (Figure 1B, upper panel). CD4+CD25+ T cells
puriﬁed from unmanipulated na¨ ıve mice showed a basal
level of phosphorylated STAT1a (Figure 1B, upper panel,
lane 1). The level of STAT1 phosphorylation in alloantigen-
primed CD4+CD25+ T cells was slightly increased, i.e.
1.4 times higher than that in naive CD4+CD25+ T cells
(Figure 1B, upper panel, lane 3). Interestingly, tolerized
CD4+CD25+ T cells with enhanced regulatory activity sig-
niﬁcantly increased phosphorylation of both a and b iso-
forms of STAT1; of the order of two- to three-fold higher
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than that in na¨ ıve CD4+CD25+ T cells (Figure 1B, up-
per panel, lane 2) (p < 0.05). Notably, the phosphoryla-
tion level of STAT5 was not signiﬁcantly changed in to-
lerized CD4+CD25+ T cells when compared to that in
na¨ ıve controls (Figure 1C). CD4+CD25− T cells activated
in the presence of IL-2 in vitro were used as a positive
control that showed a higher level of STAT5 phosphory-
lation (Figure 1C). This ﬁnding demonstrates that STAT1,
but not STAT5 activation is increased in alloantigen reactive
CD4+CD25+ T cells from tolerized mice.
To make sure that tolerized CD4+CD25+ T cells had reg-
ulatory activity and were not recently activated T cells,
ERK1/2 activation, a consequent event of T-cell activation,
was evaluated by immunoblotting. ERK1/2 phosphoryla-
tion levels in tolerized CD4+CD25+ T cells were compara-
ble to the basal level of ERK1/2 phosphorylation in na¨ ıve
CD4+CD25+ T cells, whereas increased ERK1/2 phospho-
rylation was observed in recently activated alloantigen-
primed CD4+CD25+ T cells (Figure 1B, middle panel and
lower histogram).
To further examine whether CD4+Foxp3+ T cells from to-
lerized mice could exhibit increased STAT1 phosphoryla-
tion levels at the single-cell level, spleen cells from either
tolerized C57BL/6 mice or unmanipulated na¨ ıve C57BL/6
mice were analyzed for surface CD4 and intracellular Foxp3
and phospho-STAT1 levels by FACS. CD4+Foxp3+ T cells
from the tolerized mice showed approximately a two-fold
increase in STAT1 phosphorylation compared to that de-
tected in CD4+Foxp3+ T cells puriﬁed from naive mice
(Figure 1D; the percentage of p-STAT1 positive cells was
22.4 ± 0.1% from tolerized mice vs. 11.7 ± 0.9% from
naive controls; mean ± SD; n = 3 mice per group). We fur-
ther conﬁrmed this result using CD4+Foxp3/GFP+ T cells
from tolerized Foxp3gfp.KI mice, which also exhibited en-
hanced STAT1 phosphorylation levels compared to their
na¨ ıveoralloantigen-primedcounterparts(datanotshown).
Alloantigen reactive STAT1-deﬁcient Tregs fail
to control allograft rejection
Because tolerized CD4+CD25+Foxp3+ T cells exhibit the
enhanced STAT1 activation (Figure 1), it was important
to investigate whether the regulatory activity of tolerized
CD4+CD25+ T cells was dependent on STAT1. 4 × 105
CD4+CD25+ T cells from either STAT1−/− or wild type
(WT) tolerized 129S6/SvEv mice were adoptively trans-
ferred into 129S6/SvEv Rag−/− mice together with 2 × 105
CD4+CD25− Tcellsfromunmanipulated129S6/SvEvna¨ ıve
mice 1 day before a BALB/c skin graft was transplanted.
Cotransfer of WT tolerized CD4+CD25+ T cells along with
the CD4+CD25− T cells prevented rejection (Figure 2;
MST = 82 days). In contrast, cotransfer of STAT1-deﬁcient
CD4+CD25+ T cells from tolerized mice completely abro-
gated their regulatory capacity (Figure 2; MST = 29.5 days,
p < 0.0001). Next, we compared the proliferative response
of CD4+CD25− T cells from naive mice in the presence
of tolerized Tregs that were pretreated with Fludarabine,
an inhibitor against STAT1 activity in vitro (19). Figure S1
showsthatinhibitionofSTAT1activitybyﬂudarabineblocks
the suppressive function of tolerized CD4+CD25+Tregs
in vitro, while inhibition of MAP kinase activity does not af-
fectTregsfunction.TheseobservationsindicatethatSTAT1
activation is related to the suppressive function of tolerized
Tregs and are consistent with the data obtained using to-
lerized Tregs isolated from STAT1-deﬁcient mice.
STAT1 activation in alloantigen-tolerized Tregs
is dependent on IFN-c production
Next, we measured IFN-c secretion by tolerized or na¨ ıve
CD4+Foxp3+ and CD4+Foxp3− T cells at the single-cell
level by FACS analysis. A total of 11.9 ± 0.28% of
CD4+Foxp3+ T cells from tolerized mice produced IFN-
c compared to 2.5 ± 0.14% of na¨ ıve CD4+Foxp3+ cells.
Further, it was noted that CD4+Foxp3+ T cells greatly
increased IFN-c production compared to CD4+Foxp3− T
cellsintolerizedmice(11.9±0.28%vs.3.2±0.56%;n=3
mice per group; Figure 3A) and that this phenotype was
alsoseeninna¨ ıvemicebuttoalesser degree(2.5±0.14%
vs. 1.02 ± 0.11%). These data demonstrate that tolerized
CD4+Foxp3+ T cells produce signiﬁcantly higher levels of
IFN-c than na¨ ıve CD4+Foxp3+ T cells.
In addition to IFN-c, other stimuli including IFN-a and
platelet-derived growth factor also affect STAT1 phos-
phorylation (20,21). We next determined whether the in-
creased STAT1 phosphorylation observed in Tregs from
tolerized mice was caused by IFN-c in vivo. STAT1 acti-
vation was assessed in CD4+CD25+ T cells isolated from
IFN-c–deﬁcient versus WT tolerized mice (Figure 3B). The
level of STAT1 phosphorylation in IFN-c–deﬁcient tolerized
CD4+CD25+ T cells was markedly reduced compared to
that observed in WT tolerized CD4+CD25+ T cells (Fig-
ure3B,upperpanel,lane1vs.lane2;andlowerhistogram).
Our previous ﬁndings demonstrated that Tregs generated
in IFN-c–deﬁcient mice have impaired suppressive func-
tionandabilitytocontrolskingraftrejection(adoptivetrans-
fer of na¨ ıve Teff and IFN-c −/− Tregs resulted in seven out
of nine mice rejecting their skin grafts) (7). Together, these
data indicate that IFN-c produced by Tregs might enhance
STAT1 activation thereby modifying Tregs function.
Enhanced STAT1 activation in tolerized CD4+CD25+
T cells is dependent on IFN-c receptor ligation
To ask whether the IFN-cR expressed by CD4+CD25+ T
cells in tolerized mice was responsible for IFN-c–induced
STAT1 phosphorylation, we ﬁrst conﬁrmed that IFN-cRs
was expressed on CD4+CD25+ T cells (Figure S2). Exoge-
nous IFN-c treatment signiﬁcantly increased the level of
STAT1a phosphorylation in WT CD4+CD25+ T cells, which
was 2.7-fold higher than the basal level in na¨ ıve untreated
CD4+CD25+ T cells (Figure 4A, lane 2 vs. lane 1, p <
0.01). In contrast, STAT1a phosphorylation remained at
the basal level in CD4+CD25+ T cells from IFN-cR−/− mice
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Figure 2: STAT1-deﬁcient CD4+
CD25+ T cells from tolerized mice
fail to prevent skin allograft re-
jection. Cotransfer of 4 × 105
CD4+CD25+ T cells from tolerized
WT mice (Tolerized Tregs) along
with 2 × 105 Teff into 129S6/SvEv
Rag2−/− recipientspreventsrejection
of BALB/c skin grafts (MST = 82
days, n = 8), whereas cotransfer of
4 × 105 CD4+CD25+ T cells from
STAT1−/− tolerized mice and 2 × 105
Teff fails to prevent skin graft rejec-
tion (MST = 29.5 days, n = 8, p <
0.0001, tolerized WT Tregs vs. toler-
ized STAT1−/− Tregs). Upper images
are typical accepted transplanted
skin (left) and rejected transplanted
skin (right). The data shown are
representative of three independent
experiments.
after exogenous IFN-c stimulation (Figure 4A, upper panel,
lane 3). Next, we investigated whether enhanced intrinsic
IFN-c production by tolerized CD4+CD25+ T cells could
directly ligate IFN-cRs on the CD4+CD25+ T cells them-
selves and thus modulate STAT1 activity. Approximately
four-fold higher levels of STAT1a phosphorylation were ob-
served in WT tolerized CD4+CD25+ T cells than in IFN-
cR−/− CD4+CD25+ T cells (Figure 4B; p < 0.01; n = 3). It is
worth noting that the STAT1a phosphorylation level in IFN-
cR−/− tolerized CD4+CD25+ T cells was even lower than
that detected in alloantigen-primed WT mice (Figure 4B,
upper panel, lane 1 vs. lane 2). We also observed that
IFN-cR-–deﬁcient Tregs had a reduced suppressive ability
invivo (fouroutofsixmicereconstitutedwithna¨ ıveTeff and
IFN-cR−/− Tregs rejected allogeneic skin grafts, data not
shown). These data suggest that IFN-cR is important for
STAT1activationintolerizedTregsandthatincreasedIFN-c
production in tolerized Tregs might ligate IFN-c receptors
on themselves to induce the intracellular JAK-STAT1 sig-
naling pathway in an autocrine manner.
Comparable levels of Foxp3 expression were detected in
CD4+CD25+ Tcellsfromunmanipulatedna¨ ıve,alloantigen-
primedandtolerizedmice(FigureS3A).Thepercentagesof
Foxp3 positive cells in CD4+CD25+ T cells from unmanip-
ulated na¨ ıve, alloantigen-primed and tolerized mice were
also comparable (data not shown). Importantly, expres-
sion of Foxp3 by CD4+CD25+ cells puriﬁed from STAT1−/−
or IFN-cR−/− mice was equivalent to that from WT Tregs
(Figure S3B). These data indicate that IFN-c–STAT1 signal-
ing plays a key role in the regulatory function of alloantigen-
tolerized Tregs in vivo without affecting Foxp3 expression.
The down-regulated PKB/AKT phosphorylation in
tolerized CD4+CD25+ Tregs is STAT1 dependent
A link between JAK-STAT1 activation and PKB/AKT ac-
tivation has been reported in erythroblasts in response
to erythropoietin (22). However, it is not known whether
IFN-c–induced JAK-STAT1 activation controls PKB/AKT ac-
tivation in CD4+CD25+ Tregs. To answer this question,
the phosphorylation level of PKB/AKT was ﬁrst mea-
sured in tolerized CD4+CD25+ T cells by immunoblotting
with anti-phospho-PKB/AKT (S472/473) mAb. Compared
to those from unmanipulated na¨ ıve mice, the phospho-
rylation level of PKB/AKT was signiﬁcantly decreased in
tolerized CD4+CD25+ T cells (i.e. only R = 0.47 ± 0.22;
p < 0.05; Figure 5A). Recently activated CD4+CD25+ T
cells from alloantigen-primed mice showed a comparable
level of phospho-AKT compared to na¨ ıve CD4+CD25+ T
cells (R = 1.05 ± 0.11; Figure 5A). Next, it was important
to address whether downregulation of PKB/AKT activation
in tolerized CD4+CD25+ T cells was STAT1 dependent.
Interestingly, the level of phospho-AKT was restored in
CD4+CD25+ T cells from STAT1-deﬁcient tolerized mice,
such that it was comparable to those from either na¨ ıve
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Figure 3: IFN-c production is upregulated in CD4+Foxp3+ T cells from tolerized mice. Splenocytes were isolated from tolerized or
unmanipulated na¨ ıve mice. Surface CD4+ together with intracellular Foxp3 and IFN-c were measured by FACS analysis. The FACS proﬁles
shown are representative of three independent experiments (mean ± SD, n = 3, ∗∗p < 0.01). (B) Upregulation of STAT1 phosphorylation
in CD4+CD25+ T cells from tolerized mice is IFN-c dependent. The phosphorylation levels of STAT1a and b in CD4+CD25+ T cells from
tolerized IFN-c −/−, WT mice or alloantigen-primed WT mice were shown by anti-p-STAT1 immunoblotting (upper panel). Data shown are
representative of at least three independent experiments (∗∗p < 0.01).
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Figure 4: STAT1 phosphorylation is dependent on IFN-c receptor.( A )N a ¨ ıve CD4+CD25+ T cells respond to IFN-c via their IFN-cR.
CD4+CD25+ T cells from na¨ ı v eW To rI F N - cR−/− mice were treated with or without exogenous IFN-c (2 U/lL) for 20 min, followed
by immunoblotting with anti-p-STAT1a and b (upper panel). (B) Upregulation of STAT1 phosphorylation in Tregs from tolerized mice
is IFN-c receptor dependent. STAT1a phosphorylation levels in CD4+CD25+ T cells puriﬁed from either tolerized IFN-cR−/− or WT
mice or alloantigen-primed WT mice were shown by anti-phospho-STAT1 blotting (upper panel). Data shown are representative of three
independent experiments (∗p < 0.05, ∗∗p < 0.01).
WT mice or na¨ ıve/alloantigen-primed STAT1-deﬁcient mice
(Figure 5B).
These data together indicate that tolerized Tregs upregu-
late IFN-c production, which enhances STAT1 activation,
but suppresses STAT1-dependent AKT activation. This sig-
naling pathway is important for the capacity of tolerized
Tregs to prevent allogeneic skin graft rejection in vivo.
Discussion
Here we demonstrate that enhanced IFN-c produced
by CD4+CD25+Foxp3+ Tregs from mice tolerized to al-
loantigen in vivo can ligate IFN-c receptors on the Tregs
themselves to upregulate STAT1 activation and decrease
PKB/AKT activation (Figures 1, 3, 4 and 5). By contrast,
STAT5 or ERK phosphorylation/activation is not affected
(Figure 1B, C). Importantly, the enhanced STAT1 activation
and decreased AKT activation are in the same signaling
pathway induced by IFN-c in Tregs (Figure 5B), and is re-
quired for alloantigen reactive Tregs from tolerized mice to
control allogeneic skin graft rejection in vivo (Figure 2).
It was interesting to note that CD4+Foxp3+ Tregs showed
signiﬁcantlyincreasedSTAT1phosphorylationcomparedto
CD4+Foxp3− T cells from either unmanipulated na¨ ıve mice
ortolerizedmice(Figure1DandSupportingFigureS1).This
might indicate that compared to CD4+Foxp3− cells in the
samemicroenvironment,CD4+Foxp3+ Tregscanlowerthe
threshold to activate STAT1 in response to the local pro-
duction of IFN-c in vivo by Tregs themselves or by other
cell types. In addition, it was noted that alloantigen reac-
tive CD4+Foxp3+ Tregs further increase IFN-c production
compared to na¨ ıve Tregs (Figure 3A). This might be one of
thecritical sourcesof IFN-c withinthemicroenvironments,
thatisthegraftandthedraininglymphoidtissue(23)where
alloantigen reactive Tregs respond to IFN-c and enhance
STAT1 activity in vivo. Importantly, we found that STAT1
deﬁciency impaired the suppressive function of tolerized
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Tregs in vivo (Figure 2). Others have also demonstrated
that STAT1-deﬁcient mice have an increased susceptibility
to autoimmune disease that is linked to the presence of a
reduced number of Tregs (10).
Werecentlyshowedthatintheearlyphaseoftheresponse
after transplantation, Tregs are resident in the draining lym-
phoidtissuewheretheycanpreventtheprimingofeffector
T cells. Later in the response, Tregs migrate to the graft
where they control effector T-cell populations to prevent
the development of memory T cells (23). It is possible that
these alloantigen-speciﬁc Tregs from tolerized mice might
be preferentially recruited to the graft site in vivo, since
the grafted skin provides alloantigen that can be presented
by local antigen-presenting cells (APCs) to attract these
alloantigen reactive Tregs. Moreover, local multiple stimuli
suchasIFN-c mightfurtherenhanceSTAT1activityinTregs
to maintain their presence within the graft and to enhance
their regulatory role. Consistent with this hypothesis, it
has been suggested that IFN-c inhibits monocyte migra-
tion and traps these cells at inﬂammation sites through
the downstream STAT1 (24). It would be interesting to fur-
ther investigate whether IFN-c–triggered JAK-STAT1 sig-
nals plays an important role in the recruitment and main-
tenance of Foxp3+ T cells at inﬂammatory sites, such as a
graft.
Another important observation is that STAT1 activation
was abrogated in CD4+CD25+ Tregs from tolerized IFN-c–
deﬁcient mice (Figure 3B) as well as from IFN-cR–deﬁcient
mice (Figure 4B). These data suggest a model that when
CD4+CD25+Foxp3+ T cells in tolerized mice reencounter
alloantigen they upregulate IFN-c production into the local
microenvironment, such that where IFN-c ligates IFN-c
receptors on the Tregs themselves it induces JAK-STAT1
signaling through an autocrine loop (Figure 5C), thus en-
hancing their regulatory function to protect the graft. This
observation is consistent with ﬁndings from other labora-
tories, demonstrating that IFN-c exerts its effects on cells
by interacting with its speciﬁc receptors (8). The source
of IFN-c may not only come from the Tregs themselves
but also from other cell types, including recently acti-
vated Th1 cells and NK cells and APCs (8). Further, IFN-
c also affects the function of other cell types, such as
the expression of indoleamine-2,3-dioxygenase (IDO) by
macrophages or dendritic cells (DCs). IDO-induced trypto-
phan breakdown is necessary for maintenance of various
aspects of immune tolerance (25). Interestingly, IFN-cR–
deﬁcient APCs abrogated IDO expression when exposed
to alloantigen reactive Tregs and this resulted in the rejec-
tion of transplanted skin (B. Wei et al., unpublished data).
These ﬁndings support a model whereby IFN-c produced
by tolerized Tregs might not only directly ligate IFN-c re-
ceptors to induce JAK-STAT1 signaling to inﬂuence the
function of the Tregs themselves, but also induce IDO ex-
pression in APCs to indirectly regulate tolerance induction
(Figure 5C).
IFN-c has been reported to display inhibitory activity
against Th17 cells that have been reported to play a
pathogenic role in type I diabetes and cause inﬂamma-
tion (26). Although Th17 cell development does not require
STAT1 signaling (27), it is likely that the enhanced IFN-c
production by alloantigen reactive Tregs might inhibit the
function of the Th17 lineage while favoring the function
of Tregs in the graft. These combined inﬂuences might
enhance the overall protective effects of Tregs promoting
graft survival.
In summary, our study demonstrates that the enhanced
IFN-c production by alloantigen reactive Tregs from toler-
ized mice can ligate IFN-cR on Tregs cells themselves to
upregulate STAT1 activation and downregulate PKB/AKT
activation.Further,theIFN-c triggeredSTAT1-PKB/AKTsig-
naling pathway increases the capacity of alloantigen reac-
tive Tregs to prevent allograft rejection in vivo. This study
also provides a molecular mechanism to support the func-
tional data previously reported in models of autoimmunity
(6) and transplantation (7). It is important to understand if
these observations in mice have relevance to the function
of human Tregs. Our preliminary data show that human
CD4+CD25hi Tregs also have the capacity to secrete IFN-c
upon restimulation (Figure S4). We are currently investi-
gating whether IFN-c plays a role in the function of human
Tregs as this may help us to understand whether it is possi-
ble to target IFN-c–induced JAK-STAT1-AKT signaling path-
waystoprolongallograftsurvival,preventgraft-versus-host
disease or treat autoimmune diseases.
← −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Figure 5: STAT1-dependent PKB/AKT phosphorylation is down-regulated in tolerized CD4+CD25+ Tregs in vivo. (A) Lysates from
tolerized CD4+CD25+ T cells, alloantigen-primed CD4+CD25+ or na¨ ıve CD4+CD25+ T cells were prepared for immunoblotting with anti-
phospho-PKB/AKT (upper panel) and anti-PKB/AKT1/2 Ab (lower panel) (∗p < 0.05). (B) Na¨ ıve WT, na¨ ıve STAT1−/− CD4+CD25+, tolerized
STAT1−/− CD4+CD25+ or alloantigen-primed STAT1−/− CD4+CD25+ were prepared for immonoblotting with anti-phospho-PKB/AKT
Ab (upper panel) and anti-PKB/AKT1/2 Ab (lower panel). Data shown are representative of at least three independent experiments. (C)
Model: IFN-c triggered JAK-STAT1-PKB/AKT signalling pathway controls the function of CD4+CD25+Foxp3+ regulatory T cells in vivo in
an autocrine/paracrine manner. Tolerized CD4+CD25+Foxp3+ Tregs adapted by alloantigen and anti-CD4 can upregulate IFN-c secretion.
The IFN-c released by Tregs in the local microenvironment might ligate the IFN-c receptor on Tregs themselves to induce the JAK-STAT1
signalling pathway in an autocrine manner. APCs could also provide IFN-c that might upregulate the JAK-STAT1 pathway in Tregs in a
paracrine manner. Furthermore, IFN-c triggers STAT1-dependent downregulation of PKB/AKT activation in Tregs. The up-regulated STAT1
activation and down-regulated PKB/AKT activation regulates the suppressive function of Tregs to protect the graft in vivo.
78 American Journal of Transplantation 2010; 10: 69–80STAT1-AKT Signaling Inﬂuences Tregs Function
Acknowledgments
The authors thank Dr. Nick D.Jones for excellent technical advice and Dr.
Elaine Long for critical reading of the paper. The authors also thank the staff
in the Biomedical Services facility at the John Radcliffe Hospital, for their
excellent care of the mice used in this study. This work was supported by
grants from The Wellcome Trust, BBSRC and European Union through the
RISET Integrated Project.
References
1. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation toler-
ance. Nat Rev Immunol 2003; 3: 199–210.
2. Kitching AR, Turner AL, Semple T et al. Experimental autoimmune
anti-glomerular basement membrane glomerulonephritis: A pro-
tective role for IFN-gamma. J Am Soc Nephrol 2004; 15: 1764–
1774.
3. KoniecznyBT,DaiZ,ElwoodETetal.IFN-gammaiscriticalforlong-
term allograft survival induced by blocking the CD28 and CD40
ligand T cell costimulation pathways. J Immunol 1998; 160: 2059–
2064.
4. Yu XZ, Albert MH, Martin PJ, Anasetti C. CD28 ligation induces
transplantation tolerance by IFN-gamma-dependent depletion of
T cells that recognize alloantigens. J Clin Invest 2004; 113: 1624–
1630.
5. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent
developmental program in mature regulatory T cells requires con-
tinued expression of Foxp3. Nat Immunol 2007; 8: 277–284.
6. Kelchtermans H, De Klerck B, Mitera T et al. Defective
CD4+CD25+ regulatory T cell functioning in collagen-induced
arthritis: An important factor in pathogenesis, counter-regulated by
endogenous IFN-gamma. Arthritis Res Ther 2005; 7: R402–R415.
7. Sawitzki B, Kingsley CI, Oliveira V, Karim M, Herber M, Wood KJ.
IFN-gamma production by alloantigen-reactive regulatory T cells is
important for their regulatory function in vivo. J Exp Med 2005;
201: 1925–1935.
8. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: A
paradigmforcytokinereceptorsignaling.AnnuRevImmunol1997;
15: 563–591.
9. Ramana CV, Gil MP, Schreiber RD, Stark GR. Stat1-dependent
and -independent pathways in IFN-gamma-dependent signaling.
Trends Immunol 2002; 23: 96–101.
10. Nishibori T, Tanabe Y, Su L, David M. Impaired development of
CD4+ CD25+ regulatory T cells in the absence of STAT1: In-
creased susceptibility to autoimmune disease. J Exp Med 2004;
199: 25–34.
11. Bensinger SJ, Walsh PT, Zhang J et al. Distinct IL-2 receptor sig-
naling pattern in CD4+CD25+ regulatory T cells. J Immunol 2004;
172: 5287–5296.
12. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates
de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008;
205: 565–574.
13. Sauer S, Bruno L, Hertweck A et al. T cell receptor signaling con-
trols Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad
Sci USA 2008; 105: 7797–7802.
14. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells
and immune tolerance. Cell 2008; 133: 775–787.
15. Zorn E, Nelson EA, Mohseni M et al. IL-2 regulates FOXP3 expres-
sion in human CD4+CD25+ regulatory T cells through a STAT-
dependent mechanism and induces the expansion of these cells
in vivo. Blood 2006; 108: 1571–1579.
16. Karim M, Feng G, Wood KJ, Bushell AR. CD25+CD4+ regulatory
T cells generated by exposure to a model protein antigen prevent
allograft rejection: Antigen-speciﬁc reactivation in vivo is critical for
bystander regulation. Blood 2005; 105: 4871–4877.
17. Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regu-
latory T cells prevent graft rejection: CTLA-4- and IL-10-dependent
immunoregulation of alloresponses. J Immunol 2002; 168: 1080–
1086.
18. Yang J, Brook MO, Carvalho-Gaspar M et al. Allograft rejection
mediated by memory T cells is resistant to regulation. Proc Natl
Acad Sci USA 2007; 104: 19954–19959.
19. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosup-
pression is associated with inhibition of STAT1 signaling. Nat Med
1999; 5: 444–447.
20. Kovarik P, Stoiber D, Novy M, Decker T. Stat1 combines signals
derived from IFN-gamma and LPS receptors during macrophage
activation. EMBO J 1998; 17: 3660–3668.
21. WenZ,ZhongZ,DarnellJEJ.Maximalactivationoftranscriptionby
Stat1 and Stat3 requires both tyrosine and serine phosphorylation.
Cell 1995; 82: 241–250.
22. Halupa A, Bailey ML, Huang K, Iscove NN, Levy DE, Barber DL. A
novel role for STAT1 in regulating murine erythropoiesis: Deletion
of STAT1 results in overall reduction of erythroid progenitors and
alters their distribution. Blood 2005; 105: 552–561.
23. Carvalho-Gaspar M, Jones ND, Luo S, Martin L, Brook MO, Wood
KJ. Location and time-dependent control of rejection by regula-
tory T cells culminates in a failure to generate memory T cells. J
Immunol 2008; 180: 6640–6648.
24. Hu Y, Hu X, Boumsell L, Ivashkiv LB. IFN-gamma and STAT1 ar-
rest monocyte migration and modulate RAC/CDC42 pathways. J
Immunol 2008; 180: 8057–8065.
25. Mellor AL, Munn DH. IDO expression by dendritic cells: Toler-
ance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762–
774.
26. Jain R, Tartar DM, Gregg RK et al. Innocuous IFNgamma induced
by adjuvant-free antigen restores normoglycemia in NOD mice
through inhibition of IL-17 production. J Exp Med 2008; 205: 207–
218.
27. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-
producing CD4+ effector T cells develop via a lineage distinct
from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:
1123–1132.
28. WeiB,daRochaDiasS,WangH,RuddCE.CTL-associatedantigen-
4 ligation induces rapid T cell polarization that depends on phos-
phatidylinositol 3-kinase, Vav-1, Cdc42, and myosin light chain ki-
nase. J Immunol 2007; 179: 400–408.
Supporting Information
Additional Supporting Information may be found in the on-
line version of this article:
Figure S1. CD4+CD25+ T cells with STAT1 inhibition
fail to suppress T-cell proliferation. Puriﬁed CD4+CD25−
T cells (1 × 105 cells/well) were cultured with UV-irradiated
TDS (T-cell–depleted splenocytes, 5 × 105 cells/well) in
a 96-well round-bottom plate. For stimulation, 1 lg/mL
anti-CD3 antibody was added. To analyze the suppres-
sive properties of Tregs, syngeneic CD4+CD25+ T cells
were pretreated with STAT1 inhibitor Fludarabine (F , 25
lM), MAPK inhibitor PD98059 (PD, 10 lM) or media con-
trol, and the indicated ratios of CD4+CD25+ Treg cells
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(between CD4+CD25− T cells and Treg cells) were added
into the 96-well round-bottom plate. After 3 days of incu-
bation, proliferation of responder T cells was determined
by [3H] thymidine incorporation (1 lCi/well) for the last 16
h of culture. These results are representative of three in-
dependent experiments (∗p < 0.05, ∗∗p < 0.01).
Figure S2. Surface expression levels of IFN-cRi n
CD4+CD25+ cells were measured by FACS as described
in Materials and Methods.
Figure S3. (A) Foxp3 expression levels are normal in
CD4+CD25+ T cells from tolerized mice or alloantigen-
primed mice. CD4+CD25+ T cells or CD4+CD25− T cells
were isolated from tolerized mice, alloantigen-primed or
na¨ ıve unmanipulated mice, and prepared for immunoblot-
ting with anti-Foxp3 mAb (upper panel) and anti-actin mAb
(lower panel). (B) IFN-c triggered STAT1 activation has no
effect on Foxp3 expression in CD4+CD25+ T cells. Spleno-
cytes from WT, STAT1−/−,I F N - cR−/− mice were recov-
ered and analyzed for CD4, CD25 and Foxp3 expression
by FACS. Data represent the percentage of Foxp3+ T cells
(left) or MFI (mean ﬂuorescence intensity) of Foxp3 stain-
ing in CD4+CD25+ populations (right). The data shown are
representative of three independent experiments.
Figure S4. Human CD4+CD25hi Foxp3+ Tregs can pro-
duce limited amounts of IFN-c. Human CD4+CD25high T
cells with regulatory activity were sorted and expanded
in vitro with anti-CD3/anti-CD28 coated beads (Miltenyi
Biotech) in the presence of IL-2. The cells were then stim-
ulated with 100 ng/mL phorbol 12-myristate 13-acetate
(PMA), 1 lM ionomycin and 2 ll/mL Golgi Stop for 5 h. Re-
covered cells were stained with ECD-anti-CD4 and PE-Cy7-
anti-CD25 before ﬁxing with Fix/Perm solution for 45 min,
then washed with permeabilization buffer and incubated
with2%ratserumfor15min.Next,cellswerestainedwith
FITC-anti-FoxP3 and PE-anti-IFN-c antibody for 30 min.
The data shown are representative of three independent
experiments.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials sup-
plied by the authors. Any queries (other than missing ma-
terial) should be directed to the corresponding author for
the article.
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